Intranasal administration of Mycobacterium bovis BCG induces superior protection against aerosol infection with Mycobacterium tuberculosis in mice

Clinical and Vaccine Immunology

Volumn 21, Issue 10, 2014, Pages 1443-1451

  Derrick, Steven C ^a   Kolibab, Kristopher ^a   Yang, Amy ^a   Morris, Sheldon L ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 11; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 24; INTERLEUKIN 27; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 9; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA; AEROSOL; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG EFFICACY; FEMALE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFECTION PREVENTION; LUNG TUBERCULOSIS; MOUSE; MYCOBACTERIUM BOVIS BCG; NONHUMAN; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; UPREGULATION; AEROSOL; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CD4+ T LYMPHOCYTE; COMPARATIVE STUDY; DISEASE MODEL; GENE EXPRESSION PROFILING; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; LUNG; MICROARRAY ANALYSIS; SECRETION (PROCESS); SPLEEN; TIME; TUBERCULOSIS;

ADMINISTRATION, INTRANASAL; AEROSOLS; ANIMALS; BCG VACCINE; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION PROFILING; LUNG; MICE, INBRED C57BL; MICROARRAY ANALYSIS; SPLEEN; TIME FACTORS; TUBERCULOSIS;

EID: 84907562485     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00394-14     Document Type: Article

References (36)

1. World Health Organization. 2014. Tuberculosis fact sheet no. 104. World Health Organization, Geneva, Switzerland. http://www.who.int/mediacentre/factsheets/fs104/en.
2. World Health Organization. 2014. Immunization, vaccines, and biologicals: tuberculosis. World Health Organization, Geneva, Switzerland; http://www.who.int/immunization/diseases/tuberculosis/en.
3. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV, Mosteller F. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698-702.
4. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, Fineberg HV. 1995. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96:29-35.
5. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, Rodrigues LC, Smith PG, Lipman M, Whiting PF, Sterne JA. 2014. Protection by BCG vaccine against tuberculosis: a systemic review of randomized controlled trials. Clin. Infect. Dis. 58:470-480. http://dx.doi.org/10.1093/cid/cit790.
6. Giri PK, Khuller GK. 2008. Is intranasal vaccination a feasible solution for tuberculosis? Expert Rev. Vaccines 7:1341-1356. http://dx.doi.org/10.1586/14760584.7.9.1341.
7. Middlebrook G. 1961. Immunological aspects of airborne infection: reactions to inhaled antigens. Bacteriol. Rev. 24:331-346.
8. Barclay WR, Busey WM, Dalgard DW, Good RC, Janicki BW, Kasik JE, Ribi E, Ulrich CE, Wolinsky E. 1973. Protection of monkeys against airborne tuberculosis by aerosol vaccination with bacillus Calmette-Guerin. Am. Rev. Respir. Dis. 107:351-358.
9. Lefford MJ. 1977. Induction and expression of immunity after BCG immunization. Infect. Immun. 18:646-653.
10. Schell RF, Ealey WF, Harding GE, Smith DW. 1974. The influence of vaccination on the course of experimental airborne tuberculosis in mice. J. Reticuloendothel. Soc. 16:131-138.
11. Orme IM, Collins FM. 1986. Aerogenic vaccination of mice with Mycobacterium bovis BCG. Tubercle 67:133-140. http://dx.doi.org/10.1016/0041-3879(86)90007-3.
12. Lagranderie M, Ravisse P, Marchal G, Gheorghiu M, Balasubramanian V, Weigeshaus EH, Smith DW. 1993. BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route. Tuber. Lung Dis. 74:38-46. http://dx.doi.org/10.1016/0962-8479(93)90067-8.
13. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AV. 2003. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guerin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J. Immunol. 171:1602-1609. http://dx.doi.org/10.4049/jimmunol.171.3.1602.
14. Chen L, Wang J, Zganiacz A, Xing Z. 2004. Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis. Infect. Immun. 72:238-246. http://dx.doi.org/10.1128/IAI.72.1.238-246.2004.
15. Nuermberger EL, Yoshimatsu T, Tyagi S, Bishai WR, Grosset JH. 2004. Paucibacillary tuberculosis in mice after prior aerosol immunization with Mycobacterium bovis BCG. Infect. Immun. 72:1065-1071. http://dx.doi.org/10.1128/IAI.72.2.1065-1071.2004.
16. Giri PK, Verma I, Khuller GK. 2006. Protective efficacy of intranasal vaccination with Mycobacterium bovis BCG against airway Mycobacterium tuberculosis challenge in mice. J. Infect. 53:350-356. http://dx.doi.org/10.1016/j.jinf.2005.12.017.
17. Rosenthal SR, McEnery JH, Raisys N. 1968. Aerogenic BCG vaccination against tuberculosis in animal and human subjects. J. Asthma Res. 5:309-323. http://dx.doi.org/10.3109/02770906809100348.
18. Cusumano CL, Jernigan JA, Waldman RH. 1975. Aerosolized BCG (Tice strain) treatment of bronchogenic carcinoma: phase I study. J. Natl. Cancer Inst. 55:275-279.
19. Garner FB, Meyer CA, White DS, Lipton A. 1975. Aerosol BCG treatment of carcinoma metastatic to the lung: a phase I study. Cancer 35: 1088-1094. http://dx.doi.org/10.1002/1097-0142(197504)35:41088::AI D-CNCR28203504113.0.CO;2-2.
20. Dalmia N, Ramsay AJ. 2012. Prime-boost approaches to tuberculosis vaccine development. Expert Rev. Vaccines 11:1221-1233. http://dx.doi.org/10.1586/erv.12.94.
21. Tameris MD, Hatherill M, Landry BS, Scriba TJ, Snowden MA, Lockhart S, Shea JE, McClain JB, Hussey GD, Hanekom WA, Mahomed H, McShane H, MVA85 Trial Study Team A. 2013. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomized, placebo-controlled phase 2b trial. Lancet 381: 1021-1028. http://dx.doi.org/10.1016/S0140-6736(13)60177-4.
22. Derrick SC, Dao D, Yang A, Kolibab K, Jacobs WR, Morris SL. 2012. Formulation of a mmaA4 gene deletion mutant of Mycobacterium bovis BCG in cationic liposomes significantly enhances protection against tuberculosis. PLoS One 7(3):e32959. http://dx.doi.org/10.1371/journal.pone.0032959.
23. Jeon BY, Derrick SC, Lim J, Kolibab K, Dheenadhayalan V, Yang AL, Kreiswirth B, Morris SL. 2008. Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice. Infect. Immun. 76:5173-5180. http://dx.doi.org/10.1128/IAI.00019-08.
24. Derrick SC, Perera LP, Dheenadhayalan V, Yang A, Kolibab K, Morris SL. 2008. The safety of post-exposure vaccination of mice infected with Mycobacterium tuberculosis. Vaccine 26:6092-6098. http://dx.doi.org/10.1016/j.vaccine.2008.09.011.
25. Darrah PA, Patel DT, De Luca PM, Lindsay RW, Davey DF, Flynn BJ, Hoff ST, Andersen P, Reed SG, Morris SL, Roederer M, Seder RA. 2007. Multifunctional TH1 cells define a correlate of vaccine mediated protection against Leishmania major. Nat. Med. 13:843-850. http://dx.doi.org/10.1038/nm1592.
26. Tonnis WF, Lexmond AJ, Frijlink HW, de Boer AH, Hinrichs LJ. 2013. Devices and formulations for pulmonary vaccination. Expert Opin. Drug Deliv. 10:1383-1397. http://dx.doi.org/10.1517/17425247.2013.810622.
27. Aguilo N, Toledo AM, Lopez-Roman EM, Perez-Herran E, Gormley E, Rullas-Trincado J, Angulo-Barturen I, Martin C. 2014. Pulmonary Mycobacterium bovis BCG vaccination confers dose-dependent superior protection compared to that of subcutaneous vaccination. Clin. Vaccine Immunol. 21:594-597. http://dx.doi.org/10.1128/CVI.00700-13.
28. Ciabattini A, Pettini E, Fiorino F, Prota G, Pozzi G, Medaglini D. 2011. Distribution of primed T cells and antigen-loaded antigen presenting cells following intranasal immunization in mice. PLoS One 6(4):e19346. http://dx.doi.org/10.1371/journal.pone.0019346.
29. Ruane D, Brane L, Reis BS, Cheong C, Poles J, Do Y, Zhu H, Velinzon K, Choi J-H, Studt N, Mayer L, Lavelle EC, Steinman RM, Mucida D, Mehandru S. 2013. Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract. J. Exp. Med. 210:1871-1888. http://dx.doi.org/10.1084/jem.20122762.
30. Wolf AJ, Desvignes L, Linas B, Banaiee N, Tamura T, Takatsu K, Ernst JD. 2008. Initiation of the adaptive immune response to Mycobacterium tuberculosis depends on antigen production in the local lymph node, not the lungs. J. Exp. Med. 205:105-115. http://dx.doi.org/10.1084/jem.20071367.
31. Willinger T, Rongvaux A, Takizawa H, Yancopoulos GD, Valenzuela DM, Murphy AJ, Auerbach W, Eynon EE, Steven S, Manz MG, Flavell RA. 2011. Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. Proc. Natl. Acad. Sci. U. S. A. 108:2390-2395. http://dx.doi.org/10.1073/pnas.1019682108.
32. Wu B, Huang C, Kato-Maeda M, Hopewell PC, Daley CL, Krensky AM, Clayberger C. 2008. IL-9 is associated with an impaired Th1 immune response in patients with tuberculosis. Clin. Immunol. 126:202-210. http://dx.doi.org/10.1016/j.clim.2007.09.009.
33. Gounni AS, Gregory B, Nutku GB, Aris F, Latifa K, Minshall E, North J, Tavernier J, Levit R, Nicolaides N, Robinson D, Hamid Q. 2000. Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils. Blood 96:163-171.
34. Fontaine RH, Cases O, Lelievre V, Mesples B, Renauld JC, Loron G, Degos V, Dournaud P, Baud O, Gressens P. 2008. IL-9/IL-9 receptor signaling selectively protects cortical neurons against developmental apoptosis. Cell. Death Differ. 15:1542-1552. http://dx.doi.org/10.1038/cdd.2008.79.
35. Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi A, Imitola J, Bettelli E, Oukka M, van Snick J, Renauld JC, Kuchroo VK, Khoury SJ. 2009. IL-9 induces differentiation of TH17 cells and enhances function of FoxP3-natural regulatory T cells. Proc. Natl. Acad. Sci. U. S. A. 106:12885-12890. http://dx.doi.org/10.1073/pnas.0812530106.
36. Turner J-E, Morrison PJ, Wilhelm C, Wilson M, Ahlfors H, Renauld J-C, Panzer U, Helmby J, Stockinger B. 2013. IL-9-mediated survival of type 2 innate lymphoid cells promotes damage control in helminthinduced lung inflammation. J. Exp. Med. 210:2951-2965. http://dx.doi.org/10.1084/jem.20130071.